Loading...
Market
Will Bharat Biotech secure a major contract with UNICEF for Hillchol (BBV131) by March 31, 2025?
3
Resolution / Starting Odds
Yes • 50%
No • 50%
UNICEF official announcements and Bharat Biotech press releases
Story
Bharat Biotech Launches Hillchol (BBV131) Oral Cholera Vaccine After Successful Trials
Aug 27, 2024, 10:39 AM
Indian vaccine manufacturer Bharat Biotech has announced the launch of its novel oral cholera vaccine, Hillchol (BBV131), following successful phase 3 trials. The vaccine, developed under license from Hilleman Laboratories, aims to address the rising global cholera cases and deaths, which have been increasing since 2021. Between early 2023 and March 2024, 824,479 cases and 5,900 deaths were reported across 31 countries. The introduction of this low-cost vaccine is considered a significant milestone in global public health efforts to combat cholera.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 10% • 25%
10-20% • 25%
20-30% • 25%
More than 30% • 25%
India • 25%
Bangladesh • 25%
Nigeria • 25%
Other • 25%
Less than 10 million doses • 25%
10-20 million doses • 25%
20-30 million doses • 25%
More than 30 million doses • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Africa CDC • 25%
Gavi • 25%
WHO • 25%
Other • 25%
GSK • 33%
Sanofi • 33%
Seqirus • 33%
